NAD+ metabolism as a target for metabolic health: have we found the silver bullet?

被引:44
|
作者
Connell, Niels J. [1 ]
Houtkooper, Riekelt H. [2 ]
Schrauwen, Patrick [1 ]
机构
[1] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Nutr & Movement Sci, Univ Singel 50,POB 616, NL-6200 MD Maastricht, Netherlands
[2] Univ Amsterdam, Amsterdam UMC, Amsterdam Gastroenterol & Metab, Lab Genet Metab Dis, Amsterdam, Netherlands
关键词
Diabetes; Energy metabolism; Human; Metabolic disease; NAD(+); Review; FATTY LIVER-DISEASE; SKELETAL-MUSCLE; NICOTINIC-ACID; MITOCHONDRIAL-FUNCTION; THERAPEUTIC TARGET; INSULIN-RESISTANCE; SIRT1; IMPROVES; EXERCISE; PHARMACOKINETICS;
D O I
10.1007/s00125-019-4831-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
NAD(+) has gone in and out of fashion within the scientific community a number of times since its discovery in the early 1900s. Over the last decade, NAD(+) has emerged as a potential target for combatting metabolic disturbances and the mitochondrial dysfunction that is mediated through sirtuin (SIRT) enzymes. The beneficial metabolic effects of the NAD(+)/SIRT axis have triggered an increased interest in NAD(+) as an enhancer of energy metabolism. As a result, a myriad of publications have focused on NAD(+) metabolism, with the majority of the work having been performed using in vitro models, and in vivo work largely consisting of interventions in Caenorhabditis elegans and rodents. Human intervention trials, on the other hand, are scarce. The aim of this review is to provide an overview of the state-of-the-art on influencing NAD(+) metabolism in humans and to set the stage for what the future of this exciting field may hold.
引用
收藏
页码:888 / 899
页数:12
相关论文
共 27 条
  • [21] Population Trends and Long-term Outlook for Oropharyngeal Cancer Have We Found a Silver Lining?
    Osazuwa-Peters, Nosayaba
    Davies, Louise
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (02) : 97 - 98
  • [22] Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?
    Huo, Teh-Ia
    Ho, Shu-Yein
    Hsu, Chia-Yang
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (12) : 2923 - 2923
  • [23] Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38: Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome (vol 62, pg 1084, 2013)
    Escande, Carlos
    Nin, Veronica
    Price, Nathan L.
    Capellini, Verena
    Gomes, Ana P.
    Barbosa, Maria Thereza
    O'Neil, Luke
    White, Thomas A.
    Sinclair, David A.
    Chini, Eduardo N.
    DIABETES, 2014, 63 (04) : 1428 - 1428
  • [24] Functional food addressing heart health: do we have to target the gut microbiota?
    Ryan, Paul M.
    Ross, Reynolds Paul
    Fitzgerald, Gerald F.
    Caplice, Noel M.
    Stanton, Catherine
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2015, 18 (06): : 566 - 571
  • [25] Enhance Trial: Effects of NAD3® on Hallmarks of Aging and Clinical Endpoints of Health in Middle Aged Adults: A Subset Analysis Focused on Blood Cell NAD+ Concentrations and Lipid Metabolism
    Roberts, Michael D.
    Osburn, Shelby C.
    Godwin, Joshua S.
    Ruple, Bradley A.
    La Monica, Michael B.
    Raub, Betsy
    Sandrock, Jennifer E.
    Ziegenfuss, Tim N.
    Lopez, Hector L.
    PHYSIOLOGIA, 2022, 2 (01): : 20 - 31
  • [26] Have we found a solution for health misinformation? A ten-year systematic review of health misinformation literature 2013-2022
    Zhang, Shiyi
    Zhou, Huiyu
    Zhu, Yimei
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2024, 188
  • [27] Adipose tissue NAD+-homeostasis, sirtuins and poly(ADP-ribose) polymerases - important players in mitochondrial metabolism and metabolic health
    Jokinen, Riikka
    Pirnes-Karhu, Sini
    Pietilainen, Kirsi H.
    Pirinen, Eija
    REDOX BIOLOGY, 2017, 12 : 246 - 263